 Sarah Billups
Concepts (277)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pharmacists | 18 | 2025 | 247 | 3.990 |
Why?
| | Osteoporosis | 4 | 2023 | 232 | 2.370 |
Why?
| | Osteoporotic Fractures | 3 | 2023 | 57 | 1.690 |
Why?
| | Bone Density Conservation Agents | 4 | 2022 | 70 | 1.660 |
Why?
| | Osteoporosis, Postmenopausal | 3 | 2022 | 40 | 1.240 |
Why?
| | Medication Adherence | 5 | 2025 | 558 | 1.200 |
Why?
| | Quality Improvement | 3 | 2025 | 1103 | 1.110 |
Why?
| | Pharmaceutical Services | 7 | 2020 | 81 | 1.030 |
Why?
| | Hypertension | 7 | 2023 | 1242 | 0.960 |
Why?
| | Primary Health Care | 11 | 2024 | 1680 | 0.900 |
Why?
| | Medicare Part C | 1 | 2025 | 29 | 0.890 |
Why?
| | Pharmacy Service, Hospital | 11 | 2017 | 90 | 0.800 |
Why?
| | Maternal Health Services | 1 | 2024 | 95 | 0.800 |
Why?
| | Urinary Tract Infections | 1 | 2023 | 152 | 0.760 |
Why?
| | Communicable Diseases | 1 | 2023 | 147 | 0.730 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2023 | 203 | 0.710 |
Why?
| | Blood Pressure Determination | 2 | 2018 | 148 | 0.650 |
Why?
| | Emergency Service, Hospital | 5 | 2023 | 1902 | 0.640 |
Why?
| | Patient-Centered Care | 1 | 2024 | 505 | 0.620 |
Why?
| | Retrospective Studies | 21 | 2025 | 14518 | 0.590 |
Why?
| | Patient Transfer | 1 | 2020 | 162 | 0.580 |
Why?
| | Diphosphonates | 2 | 2015 | 58 | 0.570 |
Why?
| | Education, Pharmacy, Graduate | 2 | 2016 | 17 | 0.550 |
Why?
| | Aged | 33 | 2025 | 22103 | 0.530 |
Why?
| | Anti-HIV Agents | 1 | 2023 | 754 | 0.530 |
Why?
| | Blood Pressure Monitoring, Ambulatory | 2 | 2014 | 83 | 0.530 |
Why?
| | Pharmacy Residencies | 1 | 2016 | 11 | 0.520 |
Why?
| | Community Pharmacy Services | 2 | 2013 | 43 | 0.510 |
Why?
| | Research | 2 | 2016 | 416 | 0.500 |
Why?
| | Aged, 80 and over | 11 | 2025 | 7086 | 0.500 |
Why?
| | Cohort Studies | 10 | 2025 | 5420 | 0.480 |
Why?
| | Telephone | 1 | 2015 | 167 | 0.450 |
Why?
| | Hospitals, Veterans | 9 | 2001 | 255 | 0.430 |
Why?
| | Humans | 55 | 2025 | 129650 | 0.430 |
Why?
| | Pharmacies | 1 | 2014 | 36 | 0.430 |
Why?
| | Correspondence as Topic | 2 | 2015 | 14 | 0.420 |
Why?
| | Patient Satisfaction | 5 | 2013 | 634 | 0.420 |
Why?
| | Patient Compliance | 5 | 2009 | 565 | 0.410 |
Why?
| | Female | 42 | 2025 | 68776 | 0.410 |
Why?
| | Health Maintenance Organizations | 4 | 2014 | 97 | 0.390 |
Why?
| | Professional Role | 5 | 2020 | 158 | 0.390 |
Why?
| | Colorado | 10 | 2025 | 4421 | 0.380 |
Why?
| | Prescription Drugs | 1 | 2013 | 112 | 0.380 |
Why?
| | Delivery of Health Care, Integrated | 5 | 2018 | 248 | 0.370 |
Why?
| | Insurance, Health | 1 | 2014 | 267 | 0.370 |
Why?
| | Cost Savings | 2 | 2015 | 78 | 0.360 |
Why?
| | Neuromuscular Agents | 1 | 2011 | 31 | 0.350 |
Why?
| | Drug Prescriptions | 4 | 2020 | 248 | 0.330 |
Why?
| | Drug Therapy | 2 | 2000 | 80 | 0.330 |
Why?
| | Cytochrome P-450 CYP2D6 Inhibitors | 1 | 2009 | 3 | 0.320 |
Why?
| | Nortriptyline | 1 | 2009 | 11 | 0.320 |
Why?
| | Male | 37 | 2025 | 63681 | 0.320 |
Why?
| | Drug Monitoring | 6 | 2014 | 216 | 0.310 |
Why?
| | Amitriptyline | 1 | 2009 | 20 | 0.310 |
Why?
| | Antidepressive Agents, Tricyclic | 1 | 2009 | 30 | 0.310 |
Why?
| | Antidepressive Agents, Second-Generation | 1 | 2009 | 43 | 0.310 |
Why?
| | HIV Infections | 1 | 2023 | 2720 | 0.300 |
Why?
| | Perception | 2 | 2023 | 340 | 0.300 |
Why?
| | Middle Aged | 24 | 2024 | 31154 | 0.300 |
Why?
| | Tetrahydronaphthalenes | 2 | 1998 | 30 | 0.300 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2016 | 1279 | 0.280 |
Why?
| | Calcium Channel Blockers | 2 | 1998 | 161 | 0.280 |
Why?
| | Antihypertensive Agents | 4 | 2023 | 485 | 0.280 |
Why?
| | Practice Patterns, Physicians' | 4 | 2023 | 1266 | 0.270 |
Why?
| | Benzimidazoles | 2 | 1998 | 162 | 0.270 |
Why?
| | Adult | 16 | 2024 | 35576 | 0.270 |
Why?
| | Fractures, Bone | 1 | 2012 | 392 | 0.260 |
Why?
| | Pilot Projects | 2 | 2023 | 1587 | 0.260 |
Why?
| | Managed Care Programs | 2 | 2013 | 133 | 0.250 |
Why?
| | American Heart Association | 2 | 2020 | 296 | 0.250 |
Why?
| | Lovastatin | 1 | 2005 | 37 | 0.240 |
Why?
| | United States | 15 | 2025 | 13903 | 0.240 |
Why?
| | Simvastatin | 1 | 2005 | 60 | 0.240 |
Why?
| | Patient Acceptance of Health Care | 2 | 2023 | 759 | 0.230 |
Why?
| | Ambulatory Care | 6 | 2010 | 504 | 0.230 |
Why?
| | Health Care Costs | 2 | 2014 | 367 | 0.230 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 4 | 2018 | 253 | 0.230 |
Why?
| | Heart Diseases | 1 | 2008 | 350 | 0.230 |
Why?
| | Wounds and Injuries | 1 | 2011 | 711 | 0.220 |
Why?
| | Academic Medical Centers | 2 | 2024 | 481 | 0.220 |
Why?
| | Bone Density | 2 | 2022 | 471 | 0.220 |
Why?
| | Migraine Disorders | 2 | 2020 | 101 | 0.220 |
Why?
| | Cholesterol | 2 | 2020 | 412 | 0.210 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2024 | 121 | 0.210 |
Why?
| | Absorptiometry, Photon | 1 | 2023 | 248 | 0.200 |
Why?
| | Patient Care Team | 3 | 2024 | 605 | 0.200 |
Why?
| | Denosumab | 1 | 2022 | 8 | 0.190 |
Why?
| | Blood Pressure | 2 | 2023 | 1736 | 0.190 |
Why?
| | Pregnancy Outcome | 1 | 2024 | 390 | 0.190 |
Why?
| | Practice Guidelines as Topic | 3 | 2020 | 1501 | 0.180 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2020 | 430 | 0.180 |
Why?
| | Serotonin 5-HT1 Receptor Agonists | 1 | 2020 | 4 | 0.180 |
Why?
| | Analgesics, Opioid | 2 | 2020 | 913 | 0.180 |
Why?
| | Aspirin | 1 | 2024 | 380 | 0.180 |
Why?
| | Diabetes Mellitus | 2 | 2013 | 1001 | 0.180 |
Why?
| | Quality of Health Care | 1 | 2024 | 608 | 0.160 |
Why?
| | Pregnancy Complications | 1 | 2024 | 493 | 0.160 |
Why?
| | Student Health Services | 1 | 2018 | 15 | 0.150 |
Why?
| | Glucocorticoids | 1 | 2023 | 575 | 0.150 |
Why?
| | Lithium Compounds | 1 | 2018 | 11 | 0.150 |
Why?
| | Antimanic Agents | 1 | 2018 | 18 | 0.150 |
Why?
| | Referral and Consultation | 1 | 2023 | 732 | 0.150 |
Why?
| | Product Surveillance, Postmarketing | 1 | 1998 | 62 | 0.150 |
Why?
| | Angina Pectoris | 1 | 1998 | 67 | 0.150 |
Why?
| | Young Adult | 5 | 2023 | 12426 | 0.140 |
Why?
| | Preceptorship | 1 | 2018 | 65 | 0.140 |
Why?
| | Drug Approval | 1 | 1998 | 88 | 0.140 |
Why?
| | Guideline Adherence | 3 | 2020 | 526 | 0.140 |
Why?
| | Antidepressive Agents | 2 | 2017 | 228 | 0.140 |
Why?
| | Electronic Health Records | 3 | 2022 | 975 | 0.140 |
Why?
| | Data Collection | 4 | 2014 | 650 | 0.140 |
Why?
| | Students, Pharmacy | 1 | 2018 | 96 | 0.140 |
Why?
| | Drug Interactions | 4 | 2012 | 394 | 0.130 |
Why?
| | Quality of Life | 4 | 2001 | 2704 | 0.130 |
Why?
| | Administration, Oral | 2 | 2015 | 786 | 0.120 |
Why?
| | Monitoring, Physiologic | 1 | 2017 | 268 | 0.120 |
Why?
| | Antipsychotic Agents | 1 | 2017 | 195 | 0.120 |
Why?
| | Pharmaceutical Preparations | 2 | 2016 | 171 | 0.120 |
Why?
| | Internship, Nonmedical | 1 | 2015 | 16 | 0.120 |
Why?
| | Cost-Benefit Analysis | 2 | 2015 | 569 | 0.120 |
Why?
| | Patient Readmission | 1 | 2020 | 667 | 0.110 |
Why?
| | Hematinics | 1 | 2014 | 19 | 0.110 |
Why?
| | United States Department of Veterans Affairs | 5 | 2001 | 635 | 0.110 |
Why?
| | Renal Insufficiency | 2 | 2015 | 149 | 0.110 |
Why?
| | Follow-Up Studies | 3 | 2013 | 4897 | 0.110 |
Why?
| | Educational Measurement | 1 | 2016 | 262 | 0.110 |
Why?
| | Patient Discharge | 1 | 2020 | 857 | 0.110 |
Why?
| | Lipids | 1 | 2017 | 625 | 0.110 |
Why?
| | Anti-Bacterial Agents | 1 | 2023 | 1717 | 0.110 |
Why?
| | Decision Support Systems, Clinical | 1 | 2016 | 205 | 0.100 |
Why?
| | Reminder Systems | 1 | 2015 | 174 | 0.100 |
Why?
| | Outpatients | 1 | 2016 | 370 | 0.100 |
Why?
| | Anemia | 1 | 2014 | 160 | 0.100 |
Why?
| | Colchicine | 1 | 2012 | 24 | 0.100 |
Why?
| | Gout Suppressants | 1 | 2012 | 17 | 0.100 |
Why?
| | Gout | 1 | 2012 | 33 | 0.100 |
Why?
| | Cross-Sectional Studies | 4 | 2024 | 5066 | 0.100 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2013 | 87 | 0.100 |
Why?
| | Hematologic Diseases | 1 | 2012 | 61 | 0.100 |
Why?
| | Adolescent | 4 | 2023 | 20393 | 0.100 |
Why?
| | Health Expenditures | 1 | 2014 | 179 | 0.100 |
Why?
| | Hospitalization | 2 | 2018 | 2070 | 0.100 |
Why?
| | Risk Factors | 9 | 2024 | 9765 | 0.090 |
Why?
| | Drug Therapy, Combination | 2 | 2009 | 1040 | 0.090 |
Why?
| | Pregnancy | 1 | 2024 | 6402 | 0.090 |
Why?
| | Hyperlipidemias | 3 | 2017 | 126 | 0.090 |
Why?
| | Job Satisfaction | 1 | 2013 | 203 | 0.090 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2012 | 132 | 0.090 |
Why?
| | Venous Thromboembolism | 1 | 2015 | 284 | 0.090 |
Why?
| | Evaluation Studies as Topic | 1 | 2011 | 173 | 0.090 |
Why?
| | Chronic Disease | 4 | 2008 | 1720 | 0.090 |
Why?
| | Depression | 2 | 2017 | 1307 | 0.090 |
Why?
| | Anticoagulants | 1 | 2015 | 637 | 0.090 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2022 | 2441 | 0.090 |
Why?
| | Amiodarone | 1 | 2010 | 24 | 0.080 |
Why?
| | Diazepam | 1 | 2010 | 34 | 0.080 |
Why?
| | Anti-Anxiety Agents | 1 | 2010 | 45 | 0.080 |
Why?
| | Ipratropium | 1 | 2009 | 6 | 0.080 |
Why?
| | Case-Control Studies | 3 | 2018 | 3381 | 0.080 |
Why?
| | Anti-Arrhythmia Agents | 1 | 2010 | 111 | 0.080 |
Why?
| | Mental Disorders | 1 | 2018 | 1030 | 0.080 |
Why?
| | Paroxetine | 1 | 2009 | 10 | 0.080 |
Why?
| | Cytochrome P-450 CYP2D6 | 1 | 2009 | 29 | 0.080 |
Why?
| | Heart Failure | 1 | 2022 | 2150 | 0.080 |
Why?
| | Bupropion | 1 | 2009 | 40 | 0.080 |
Why?
| | Time Factors | 4 | 2013 | 6556 | 0.080 |
Why?
| | Telemedicine | 1 | 2017 | 788 | 0.080 |
Why?
| | Kidney | 1 | 2016 | 1385 | 0.080 |
Why?
| | Mibefradil | 2 | 1998 | 7 | 0.080 |
Why?
| | Fluoxetine | 1 | 2009 | 53 | 0.080 |
Why?
| | Internet | 1 | 2013 | 617 | 0.080 |
Why?
| | Fees, Pharmaceutical | 1 | 2008 | 10 | 0.070 |
Why?
| | Bronchodilator Agents | 1 | 2009 | 243 | 0.070 |
Why?
| | Prospective Studies | 5 | 2015 | 7133 | 0.070 |
Why?
| | Blood Glucose | 1 | 2017 | 2097 | 0.070 |
Why?
| | Surveys and Questionnaires | 7 | 2018 | 5406 | 0.070 |
Why?
| | Tryptamines | 1 | 2006 | 5 | 0.060 |
Why?
| | Sumatriptan | 1 | 2006 | 8 | 0.060 |
Why?
| | Serotonin Receptor Agonists | 1 | 2006 | 28 | 0.060 |
Why?
| | Financing, Personal | 1 | 2005 | 26 | 0.060 |
Why?
| | Drugs, Generic | 1 | 2005 | 21 | 0.060 |
Why?
| | Hypolipidemic Agents | 2 | 2008 | 92 | 0.060 |
Why?
| | Drug Costs | 1 | 2005 | 100 | 0.060 |
Why?
| | Triazoles | 1 | 2006 | 152 | 0.060 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2009 | 2012 | 0.060 |
Why?
| | Incidence | 1 | 2011 | 2644 | 0.060 |
Why?
| | Mass Screening | 1 | 2012 | 1149 | 0.060 |
Why?
| | Patients | 1 | 2005 | 167 | 0.050 |
Why?
| | Anticholesteremic Agents | 1 | 2005 | 150 | 0.050 |
Why?
| | Age Factors | 1 | 2011 | 3144 | 0.050 |
Why?
| | Medical Records Systems, Computerized | 2 | 2006 | 93 | 0.050 |
Why?
| | Cholesterol, LDL | 1 | 2005 | 358 | 0.050 |
Why?
| | Proton Pump Inhibitors | 1 | 2024 | 100 | 0.050 |
Why?
| | Secondary Prevention | 1 | 2024 | 218 | 0.050 |
Why?
| | Sex Factors | 1 | 2009 | 1968 | 0.050 |
Why?
| | Medicaid | 2 | 2017 | 433 | 0.050 |
Why?
| | Primary Prevention | 1 | 2024 | 188 | 0.050 |
Why?
| | Sodium Potassium Chloride Symporter Inhibitors | 1 | 2022 | 15 | 0.050 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2009 | 985 | 0.050 |
Why?
| | Sodium | 1 | 2022 | 206 | 0.050 |
Why?
| | Treatment Outcome | 3 | 2006 | 10230 | 0.040 |
Why?
| | Economics, Pharmaceutical | 1 | 2000 | 9 | 0.040 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2024 | 442 | 0.040 |
Why?
| | Cardiovascular Diseases | 2 | 2024 | 2004 | 0.040 |
Why?
| | Medication Systems, Hospital | 1 | 1999 | 9 | 0.040 |
Why?
| | Ambulatory Care Facilities | 2 | 2017 | 228 | 0.040 |
Why?
| | Veterans | 2 | 2001 | 1398 | 0.040 |
Why?
| | Federal Government | 1 | 2018 | 27 | 0.040 |
Why?
| | Community Health Centers | 1 | 2018 | 57 | 0.040 |
Why?
| | Renal Insufficiency, Chronic | 2 | 2014 | 566 | 0.040 |
Why?
| | Software | 2 | 1999 | 608 | 0.030 |
Why?
| | Outpatient Clinics, Hospital | 1 | 1998 | 82 | 0.030 |
Why?
| | Vulnerable Populations | 1 | 2018 | 158 | 0.030 |
Why?
| | Glucose | 1 | 2022 | 1003 | 0.030 |
Why?
| | Counseling | 1 | 2000 | 385 | 0.030 |
Why?
| | Prescription Drug Misuse | 1 | 2017 | 39 | 0.030 |
Why?
| | Drug Dosage Calculations | 1 | 2016 | 22 | 0.030 |
Why?
| | Contraindications | 1 | 2016 | 90 | 0.030 |
Why?
| | Health Status | 1 | 2001 | 755 | 0.030 |
Why?
| | International Normalized Ratio | 1 | 2015 | 46 | 0.030 |
Why?
| | Logistic Models | 1 | 2000 | 1988 | 0.030 |
Why?
| | Epoetin Alfa | 1 | 2014 | 6 | 0.030 |
Why?
| | Warfarin | 1 | 2015 | 147 | 0.030 |
Why?
| | Longitudinal Studies | 2 | 2014 | 2717 | 0.030 |
Why?
| | Pain Management | 1 | 2017 | 327 | 0.030 |
Why?
| | Erythropoietin | 1 | 2014 | 86 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 1998 | 1004 | 0.030 |
Why?
| | Publishing | 1 | 2015 | 140 | 0.030 |
Why?
| | Drug Overdose | 1 | 2017 | 322 | 0.020 |
Why?
| | Cytochrome P-450 CYP3A Inhibitors | 1 | 2012 | 18 | 0.020 |
Why?
| | Acute Disease | 1 | 2015 | 980 | 0.020 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2012 | 87 | 0.020 |
Why?
| | Recurrence | 1 | 2015 | 1007 | 0.020 |
Why?
| | Insurance, Health, Reimbursement | 1 | 2012 | 94 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2013 | 516 | 0.020 |
Why?
| | Specialization | 1 | 2013 | 145 | 0.020 |
Why?
| | Education, Pharmacy | 1 | 2013 | 119 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2014 | 1304 | 0.020 |
Why?
| | Hemorrhage | 1 | 2015 | 678 | 0.020 |
Why?
| | Commission on Professional and Hospital Activities | 1 | 2010 | 3 | 0.020 |
Why?
| | Thyrotropin | 1 | 2010 | 109 | 0.020 |
Why?
| | Alanine Transaminase | 1 | 2010 | 153 | 0.020 |
Why?
| | Opioid-Related Disorders | 1 | 2017 | 484 | 0.020 |
Why?
| | Nebulizers and Vaporizers | 1 | 2009 | 83 | 0.020 |
Why?
| | Enzyme Inhibitors | 1 | 2012 | 827 | 0.020 |
Why?
| | Data Interpretation, Statistical | 2 | 2001 | 335 | 0.020 |
Why?
| | Spirometry | 1 | 2009 | 257 | 0.020 |
Why?
| | Models, Econometric | 1 | 2008 | 33 | 0.020 |
Why?
| | Comorbidity | 1 | 2013 | 1547 | 0.020 |
Why?
| | Forced Expiratory Volume | 1 | 2009 | 510 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 1952 | 0.020 |
Why?
| | Cardiology | 1 | 2010 | 261 | 0.020 |
Why?
| | Drug Utilization | 1 | 2008 | 171 | 0.020 |
Why?
| | Electrocardiography | 1 | 2010 | 608 | 0.020 |
Why?
| | Analgesics | 1 | 2008 | 189 | 0.020 |
Why?
| | Prevalence | 1 | 2012 | 2564 | 0.020 |
Why?
| | Prognosis | 1 | 2013 | 3794 | 0.010 |
Why?
| | Child, Preschool | 1 | 2017 | 10517 | 0.010 |
Why?
| | Pain | 1 | 2008 | 789 | 0.010 |
Why?
| | Reproducibility of Results | 2 | 1999 | 3083 | 0.010 |
Why?
| | Total Quality Management | 1 | 2001 | 60 | 0.010 |
Why?
| | Health Status Indicators | 1 | 2001 | 167 | 0.010 |
Why?
| | Lipoproteins, LDL | 1 | 2000 | 127 | 0.010 |
Why?
| | Quality-Adjusted Life Years | 1 | 2000 | 106 | 0.010 |
Why?
| | Multicenter Studies as Topic | 1 | 2001 | 286 | 0.010 |
Why?
| | Treatment Refusal | 1 | 2000 | 89 | 0.010 |
Why?
| | Diabetes Complications | 1 | 2001 | 224 | 0.010 |
Why?
| | Linear Models | 1 | 2001 | 819 | 0.010 |
Why?
| | Medical Records | 1 | 1999 | 171 | 0.010 |
Why?
| | Quality Indicators, Health Care | 1 | 2001 | 298 | 0.010 |
Why?
| | Health Services Research | 1 | 2001 | 391 | 0.010 |
Why?
| | Child | 1 | 2017 | 20883 | 0.010 |
Why?
| | Attitude to Health | 1 | 2001 | 431 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2001 | 1368 | 0.010 |
Why?
| | Patient Education as Topic | 1 | 2000 | 743 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 1999 | 1838 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 1999 | 2742 | 0.010 |
Why?
|
|
Billups's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|